The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population.
2020
IntroductionThe CREATE-X study, conducted in Japan and South Korea, established capecitabine as an adjuvant treatment option for patients with triple negative breast cancer (TNBC) who have residual...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
26
References
0
Citations
NaN
KQI